Merve Yılmaz

Ms. Merve Yılmaz

Hacettepe University Faculty of Medicine
orcid
Postdoctoral Researcher - UT Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
BOBusra Ozlu
Busra Ozlu
GKGozde Kabay
Gozde Kabay
IBIlyas Bocek
Ilyas Bocek
MYMerve Yılmaz
Merve Yılmaz
APAyse Kevser Piskin
Ayse Kevser Piskin
MMMehmet Mutlu
Mehmet Mutlu

14 April 2021 in Chemosensors
Verified
Journal Article
Open access
PDF file
MYMerve Yılmaz
Merve Yılmaz
MBMonireh Bakhshpour-Yucel
Monireh Bakhshpour-Yucel
IGIlgım Göktürk
Ilgım Göktürk
AÖAyse kevser özden
Ayse kevser özden
Adil DenizliAdil Denizli
Adil Denizli
The heterogeneity and metastatic features of cancer cells lead to a great number of casualties in the world. Additionally, its diagnosis as well as its treatment is highly expensive. Therefore, development of simple but effective diagnostic systems which detect the molecular markers of cancer is of great importance. The molecular changes on cancer cell membranes serve as targets, such as HER2/neu receptor which is detected on the surface of highly metastatic breast cancer cells. We have aimed to develop a specific and simple quartz crystal microbalance (QCM)-based system to identify HER2/neu expressing breast cancer cells via a receptor-specific monoclonal antibody. First, the QCM chip was coated with polymeric nanoparticles composed of hydroxyethylmethacrylate (HEMA) and ethylene glycol dimethacrylate (EDMA). The nanoparticle coated QCM chip was then functionalized by binding of HER2/neu antibody. The breast cancer cells with/without HER2/neu receptor expression, namely, SKBR3, MDA-MB 231 and also mouse fibroblasts were passed over the chip at a rate of 10–500 cells/mL and the mass changes (Δm) on cell/cm2 unit surface of sensor were detected in real-time. The detection limit of the system was 10 cells/mL. Thus, this QCM-based HER2/neu receptor antibody functionalized system might be used effectively in the detection of HER2/neu expressing SKBR3 breast cancer cells.

1 February 2018 in Analytical Biochemistry
Verified
Journal Article
Closed access
ZUZihni Onur Uygun
Zihni Onur Uygun
ÇŞÇağdaş Şahin
Çağdaş Şahin
MYMerve Yılmaz
Merve Yılmaz
YAYasemin Akçay
Yasemin Akçay
AAAli Akdemir
Ali Akdemir
FSFerhan Sağın
Ferhan Sağın

1 April 2023 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
MYMerve Yılmaz
Merve Yılmaz
FKFuat Kaplan
Fuat Kaplan
IMIlgen Mender
Ilgen Mender
SGSergei M. Gryaznov
Sergei M. Gryaznov
ZDZ. Gunnur Dikmen
Z. Gunnur Dikmen
Cancer stem cells (CSCs) are correlated with poor clinical outcome due to their contribution to chemotherapy resistance and formation of metastasis. Multiple cell surface and enzymatic markers have been characterized to identify CSCs, which is important for diagnosis, therapy, and prognosis. This review underlines the role of CSCs and circulating tumor cells (CTCs) in tumor relapse and metastasis, the characteristics of CSC and CTC biomarkers, and the techniques used for the detection of these cells. We also summarized novel therapeutic approaches toward targeting CSCs, especially focusing on the role of immune checkpoint blockades (ICB), such as anti-programmed death 1 (anti-PD1) and anti-programmed death ligand-1 (anti-PDL1) therapies. Additionally, we address an intriguing new mechanism of action for small molecular drugs, such as telomere targeted therapy 6-thio-2’deoxyguanosine (6-thio-dG), and how it reshapes tumor microenvironment to overcome ICB resistance. There are indications, that, personalized cancer therapy targeting CSC populations in conjunction with immune-mediated strategy hold promise for the removal of residual therapy-resistant CSCs in the near future.

1 September 2018 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
MOMehmet Ozcan
Mehmet Ozcan
MGMuslum Gok
Muslum Gok
MYMerve Yılmaz
Merve Yılmaz
EBEbru Bodur
Ebru Bodur
YAYasemin Aksoy
Yasemin Aksoy
ZDZ. Gunnur Dikmen
Z. Gunnur Dikmen

1 September 2018 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
MGMuslum Gok
Muslum Gok
MOMehmet Ozcan
Mehmet Ozcan
MYMerve Yılmaz
Merve Yılmaz
CCCigdem Cicek
Cigdem Cicek
GDGunnur Dikmen
Gunnur Dikmen